The latest price target for LAVA Therapeutics (NASDAQ:LVTX) was reported by Leerink Partners on December 12, 2024. The analyst firm set a price target for $2.00 expecting LVTX to rise to within 12 months (a possible 75.44% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for LAVA Therapeutics (NASDAQ:LVTX) was provided by Leerink Partners, and LAVA Therapeutics downgraded their market perform rating.

There is no last upgrade for LAVA Therapeutics

The last downgrade for LAVA Therapeutics NV happened on December 12, 2024 when Leerink Partners changed their price target from $11 to $2 for LAVA Therapeutics NV.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LAVA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LAVA Therapeutics was filed on December 12, 2024 so you should expect the next rating to be made available sometime around December 12, 2025.

While ratings are subjective and will change, the latest LAVA Therapeutics (LVTX) rating was a downgraded with a price target of $11.00 to $2.00. The current price LAVA Therapeutics (LVTX) is trading at is $1.14, which is out of the analyst’s predicted range.